Prozac could be repurposed to treat age-related macular degeneration
Fluoxetine - best known as Prozac - protected the macula from inflammation and degeneration in mice and could become a future treatment.
List view / Grid view
Fluoxetine - best known as Prozac - protected the macula from inflammation and degeneration in mice and could become a future treatment.
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
Biologics solutions from discovery to manufacturing.
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
The absence of interleukin-36 receptor antagonist (IL-36Ra) significantly slowed down wound healing in ischemia-reperfusion injuries in mice.
The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.